Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human, Mouse, Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Peptide sequence around phosphorylation site of Serine 3291 (F-V-S(p)-P-A) derived from Human BRCA2.|
|Storage buffer||PBS, pH 7.4, with 50% glycerol|
|Contains||0.02% sodium azide|
|Tested Applications||Dilution *|
|Western Blot (WB)||1:500-1:1000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
A suggested positive control for Western blot is 293 cells.
Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
BRCA1/BRCA2-containing complex; BRCA1/BRCA2-containing complex, subunit 2; breast and ovarian cancer susceptibility gene; breast and ovarian cancer susceptibility gene, early onset; breast and ovarian cancer susceptibility protein 2; breast cancer 2 tumor suppressor; breast cancer 2, early onset; breast cancer 2, mutation 1, University of Wisconsin-Madison; breast cancer susceptibility protein 2; breast cancer susceptibility protein BRCA2; breast cancer type 2 susceptibility protein; breast cancer type 2 susceptibility protein homolog; early onset; Fanconi anemia group D1 protein; fanconi anemia group D1 protein homolog; mutant BRCA2; subunit 2
BRCA2; BRCC2; BROVCA2; FACD; FAD; FAD1; FANCD; FANCD1; GLM3; PNCA2; RAB163; XRCC11